Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 8/2007

01.08.2007 | Original Paper

Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells

verfasst von: Marjan Gharagozloo, Zahra Amirghofran

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Silymarin is a polyphenolic flavonoid that has a strong antioxidant activity and exhibits anti-carcinogenic, anti-inflammatory, and cytoprotective effects. Although its hepatoprotective effect has been well documented, the effect of silymarin on T cells is largely unknown. The purpose of this study was to analyze the effects of the silymarin on the proliferation and cell cycle progression of Jurkat cells, a human peripheral blood leukemia T cell line. Cells were incubated with various concentrations of silymarin for 24–72 h and examined for cell growth and proliferation using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and DNA 5-bromo 2′-deoxyuridine (BrdU) colorimetric assays. Cell cycle analysis by flow cytometry was also performed using propidium iodide staining. Results of the study revealed that silymarin increased proliferation of Jurkat cells at 50–400 μM concentrations with 24 h exposure, confirmed by both MTT and BrdU assays. However, Jurkat incubation with silymarin at higher concentrations of 400 μM for 48 h and 200–400 μM for 72 h caused inhibition of DNA synthesis, cell cycle arrest at the G2/M phase and significant cell death. Results of the present study also revealed a similarity of cell growth patterns between Jurkat, U937 and RPMI 8866 cells. In conclusion, this study demonstrated an in vitro growth stimulatory effect of silymarin on leukemia cells with monocyte, T and B cell origin that has not been previously reported for either solid tumors or other leukemia cells, suggesting a possible specific stimulatory effect of silymarin on the key cells of the immune system.
Literatur
Zurück zum Zitat Agarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421CrossRef Agarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421CrossRef
Zurück zum Zitat Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Sajjadi SE, Hourfar H, Moayedi B (2006) Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int Immunopharmacol 6:1305–1310PubMedCrossRef Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Sajjadi SE, Hourfar H, Moayedi B (2006) Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int Immunopharmacol 6:1305–1310PubMedCrossRef
Zurück zum Zitat Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12:S17–S27PubMedCrossRef Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12:S17–S27PubMedCrossRef
Zurück zum Zitat Bruggisser R, von Daeniken K, Jundt G, Schaffner W, Tullberg-Reinert H (2002) Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med 68:445–448PubMedCrossRef Bruggisser R, von Daeniken K, Jundt G, Schaffner W, Tullberg-Reinert H (2002) Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med 68:445–448PubMedCrossRef
Zurück zum Zitat Crocenzi FA, Roma MG (2006) Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 13:1055–1074PubMedCrossRef Crocenzi FA, Roma MG (2006) Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 13:1055–1074PubMedCrossRef
Zurück zum Zitat Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ. (2005) Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65:4448–4457PubMedCrossRef Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ. (2005) Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65:4448–4457PubMedCrossRef
Zurück zum Zitat Dietzmann J, Thiel U, Ansorge S, Neumann KH, Tager M (2002) Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med 33:1347–1354PubMedCrossRef Dietzmann J, Thiel U, Ansorge S, Neumann KH, Tager M (2002) Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med 33:1347–1354PubMedCrossRef
Zurück zum Zitat Hannay JA, Yu D (2003) Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biol Ther 2:532–533PubMed Hannay JA, Yu D (2003) Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biol Ther 2:532–533PubMed
Zurück zum Zitat HemaIswarya S, Doble M (2006) Potential synergism of natural products in the treatment of cancer. Phytother Res 20:239–249PubMedCrossRef HemaIswarya S, Doble M (2006) Potential synergism of natural products in the treatment of cancer. Phytother Res 20:239–249PubMedCrossRef
Zurück zum Zitat Kanadaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT (2005) The antitumor activities of flavonoids. In Vivo 19:895–909PubMed Kanadaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT (2005) The antitumor activities of flavonoids. In Vivo 19:895–909PubMed
Zurück zum Zitat Kang SN, Lee MH, Kim KM, Cho D, Kim TS (2001) Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 61:1487–1495PubMedCrossRef Kang SN, Lee MH, Kim KM, Cho D, Kim TS (2001) Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 61:1487–1495PubMedCrossRef
Zurück zum Zitat Kren V, Walterova D (2005) Silybin and silymarin: new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:29–41PubMed Kren V, Walterova D (2005) Silybin and silymarin: new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:29–41PubMed
Zurück zum Zitat Lang I, Deak G, Nekam K, Muzes G, Gonzalez-Cabello R, Gergely P, Feher J (1988) Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Med Hung 45:287–295PubMed Lang I, Deak G, Nekam K, Muzes G, Gonzalez-Cabello R, Gergely P, Feher J (1988) Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Med Hung 45:287–295PubMed
Zurück zum Zitat Lang I, Nekam K, Deak G, Muzes G, Gonzales-Cabello R, Gergely P, Cisomos G, Feher J (1990) Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol 22:283–287PubMed Lang I, Nekam K, Deak G, Muzes G, Gonzales-Cabello R, Gergely P, Cisomos G, Feher J (1990) Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol 22:283–287PubMed
Zurück zum Zitat McCarty MF, Block KI (2006) Toward a core nutraceutical program for cancer management. Integr Cancer Ther 5:150–171PubMedCrossRef McCarty MF, Block KI (2006) Toward a core nutraceutical program for cancer management. Integr Cancer Ther 5:150–171PubMedCrossRef
Zurück zum Zitat Meroni PL, Barcellini W, Borghi MO, Vismara A, Ferraro G, Ciani D, Zanussi C (1988) Silybin inhibition of human T-lymphocyte activation. Int J Tissue React 10:177–181PubMed Meroni PL, Barcellini W, Borghi MO, Vismara A, Ferraro G, Ciani D, Zanussi C (1988) Silybin inhibition of human T-lymphocyte activation. Int J Tissue React 10:177–181PubMed
Zurück zum Zitat Middleton EJ, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751PubMed Middleton EJ, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751PubMed
Zurück zum Zitat Qi L, Singh RP, Lu Y, Agarwal R, Harrison GS, Franzusoff A, Glode LM (2003) Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther 2:526–531PubMed Qi L, Singh RP, Lu Y, Agarwal R, Harrison GS, Franzusoff A, Glode LM (2003) Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther 2:526–531PubMed
Zurück zum Zitat Sarkar FH, Li Y (2006) Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66:3347–3350PubMedCrossRef Sarkar FH, Li Y (2006) Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66:3347–3350PubMedCrossRef
Zurück zum Zitat Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G (2003) Silibinin protects mice from T cell-dependent liver injury. J Hepatol 39:333–340PubMedCrossRef Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G (2003) Silibinin protects mice from T cell-dependent liver injury. J Hepatol 39:333–340PubMedCrossRef
Zurück zum Zitat Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104:1645–1653PubMedCrossRef Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104:1645–1653PubMedCrossRef
Zurück zum Zitat Singh RP, Agarwal R (2005). Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41:1969–1979PubMedCrossRef Singh RP, Agarwal R (2005). Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41:1969–1979PubMedCrossRef
Zurück zum Zitat Singh RP, Agarwal R (2006a) Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets 7:345–354CrossRef Singh RP, Agarwal R (2006a) Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets 7:345–354CrossRef
Zurück zum Zitat Singh RP, Agarwal R (2006b) Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45:436–442 CrossRef Singh RP, Agarwal R (2006b) Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45:436–442 CrossRef
Zurück zum Zitat Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24:1188–1202PubMedCrossRef Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24:1188–1202PubMedCrossRef
Zurück zum Zitat Singh RP, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R (2006) Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther 5:1145–1153PubMedCrossRef Singh RP, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R (2006) Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther 5:1145–1153PubMedCrossRef
Zurück zum Zitat Sonnenbichler J, Zetl I (1986) Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res 213:319–331PubMed Sonnenbichler J, Zetl I (1986) Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res 213:319–331PubMed
Zurück zum Zitat Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogl S, Zetl I (1986) Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharmacol 35:538–541PubMedCrossRef Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogl S, Zetl I (1986) Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharmacol 35:538–541PubMedCrossRef
Zurück zum Zitat Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R (1999) Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 290:1375–1383PubMed Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R (1999) Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 290:1375–1383PubMed
Zurück zum Zitat Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP (1998) Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139:4756–4764PubMedCrossRef Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP (1998) Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139:4756–4764PubMedCrossRef
Zurück zum Zitat Tyagi AK, Agarwal C, Chan DC, Agarwal R (2004) Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 11:493–499PubMed Tyagi AK, Agarwal C, Chan DC, Agarwal R (2004) Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 11:493–499PubMed
Zurück zum Zitat Valenzuela A, Garrido A (1994) Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 27:105–112PubMed Valenzuela A, Garrido A (1994) Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 27:105–112PubMed
Zurück zum Zitat Wellington K, Jarvis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs 15:465–489PubMedCrossRef Wellington K, Jarvis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs 15:465–489PubMedCrossRef
Zurück zum Zitat Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS (2002) Immunostimulatory effect of Silybum marianum (milk thistle) extract. Med Sci Monit 8:BR439–BR443PubMed Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS (2002) Immunostimulatory effect of Silybum marianum (milk thistle) extract. Med Sci Monit 8:BR439–BR443PubMed
Zurück zum Zitat Zhong X, Zhu Y, Lu Q, Zhang J, Ge Z, Zheng S (2006) Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicology 227:211–216 Zhong X, Zhu Y, Lu Q, Zhang J, Ge Z, Zheng S (2006) Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicology 227:211–216
Metadaten
Titel
Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells
verfasst von
Marjan Gharagozloo
Zahra Amirghofran
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0197-x

Weitere Artikel der Ausgabe 8/2007

Journal of Cancer Research and Clinical Oncology 8/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.